<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19259331</article-id><article-id pub-id-type="pmc">2648634</article-id><article-id pub-id-type="doi">10.1155/2008/417137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nieder</surname><given-names>Carsten</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Marienhagen</surname><given-names>Kirsten</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dalhaug</surname><given-names>Astrid</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Norum</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I2"><sup>2, 3</sup></xref><xref ref-type="aff" rid="I3"/></contrib></contrib-group><aff id="I1"><sup>1</sup>Radiation Oncology Unit, Medical Department - Oncology, Nordlandssykehuset HF, 8092 Bod&#x000f8;, Norway</aff><aff id="I2"><sup>2</sup>Institute of Clinical Medicine, Faculty of Medicine, University of Troms&#x000f8;, 9037 Troms&#x000f8;, Norway</aff><aff id="I3"><sup>3</sup>Department of Oncology, University Hospital of North Norway, 9038 Troms&#x000f8;, Norway</aff><author-notes><corresp id="cor1">*Carsten Nieder: <email>carsten.nieder@nlsh.no</email></corresp><fn fn-type="other"><p>Recommended by Minesh Mehta</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>417137</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2008</year></date><date date-type="rev-recd"><day>2</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Carsten Nieder et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Newly developed systemic treatment regimens might lead to improved survival also in the subgroup of breast cancer patients that harbour brain metastases. In order to examine this hypothesis, a matched pairs analysis was performed that involved one group of patients, which were treated after these new drugs were introduced, and one group of patients, which were treated approximately 10 years earlier. The two groups were well balanced for the known prognostic factors age, KPS, extracranial disease status, and recursive partitioning analysis class, as well as for the extent of brain treatment. The results show that the use of systemic chemotherapy has increased over time, both before and after the diagnosis of brain metastases. However, such treatment was performed nearly exclusively in those patients with brain metastases that belonged to the prognostically more favourable groups. Survival after whole-brain radiotherapy has remained unchanged in patients without further active treatment. It has improved in prognostically better patients and especially patients that received active treatment, where the 1-year survival rates have almost doubled. As these patient groups were small, confirmation of the results in other series should be attempted. Nevertheless, the present results are compatible with the hypothesis that improved systemic therapy might contribute to prolonged survival in patients with brain metastases from breast cancer.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Whole brain  radiotherapy (WBRT) continues to representan important palliative treatment option for patients with brain metastasesfrom breast cancer. Median overall survival typically is limited to 4&#x02013;6 months [<xref ref-type="bibr" rid="B1">1</xref>]. However,many patients have active extracranial disease and eventually die fromextracranial cancer progression. Within the last decade, several important newtreatment options for metastatic breast cancer became available, for example,trastuzumab, taxane-based chemotherapy, capecitabine, and more effectivearomatase inhibitors. Therefore, the possibility exists that more effectivesystemic treatment might lead to improved survival also in the subgroup ofpatients harbouring brain metastases. In order to examine this hypothesis, amatched pairs analysis was performed that involved one group of patients, whichwere treated after these new drugs were introduced, and one group of patients,which were treated approximately 10 years earlier.</p></sec><sec sec-type="section" id="sec2"><title>2. Patients and Methods</title><p>The contemporary groupincluded all patients with brain metastases from breast cancer, which receivedWBRT with 10 fractions of 3 Gy between 2000 and 2007 at the University Hospitalof North-Norway. The patients (<italic>n</italic> = 32) were identified from the database of theRadiation Oncology facility. No patients with carcinomatous meningitis wereincluded. Positron emission tomography for staging was not available. Ahistorical control group treated with the same WBRT regimen between 1987 and 1997was generated. From this larger group (<italic>n</italic> = 47), patients were selected for amatched pairs analysis without survival information available at the time ofmatching. To obtain two groups with comparable baseline characteristics, twomatching criteria were used: prognostic class according to the publishedrecursive partitioning analysis (RPA class) [<xref ref-type="bibr" rid="B2">3</xref>, <xref ref-type="bibr" rid="B3">4</xref>] and the use of additionallocal treatment for relapses after WBRT, for example, radiosurgery (RS) orsurgical resection. Information on primary tumour features, such as hormonereceptor status and HER2 receptor status, was not available in the historicalgroup. Information on lymphopenia [<xref ref-type="bibr" rid="B4">5</xref>, <xref ref-type="bibr" rid="B5">6</xref>] was not available at all. We used the Kaplan-Meiermethod to generate actuarial survival curves. These were compared with the logrank test. Wilcoxon- and Kruskal-Wallis tests were used to compare the baselinecharacteristics between the two groups. A <italic>P</italic>-value &#x0003c;.05 wasconsidered statistically significant.</p></sec><sec sec-type="section" id="sec3"><title>3. Results</title><p>				<xref ref-type="table" rid="tab1">Table 1</xref> shows the patientcharacteristics for the contemporary group and the matched group of 32historical patients. As can be seen, the groups were balanced for theestablished prognostic factors. More patients in the contemporary group hadreceived chemotherapy before diagnosis of brain metastases. Time to developmentof brain metastases was significantly longer. The fact that more patients inthe historical group were recorded to have had single brain metastases apparentlywas not related to increased use of magnetic resonance imaging in recent years.</p><p>The majority of patients inthe contemporary group were lymph node positive, hormone receptor negative, andHER-2 positive. Neither hormone receptor status nor HER-2 status was statisticallysignificant prognostic factor in this group (<italic>P</italic> &#x0003e; .3). Only 4 patientshad not received systemic treatment, 2 had received endocrine treatment only,and 26 had received chemotherapy before development of brain metastases (5patients had 3 different lines of chemotherapy). Twelve patients remainedwithout systemic treatment after WBRT, 5 received endocrine treatment only, 11one line of chemotherapy, and 4 at least 2 lines of chemotherapy. Threepatients received trastuzumab-containing treatment after WBRT. As this was amatching criterion, 3 patients in each group received RS or surgical resectionfor progressive brain metastases. As a striking difference, only 8 patients inthe historical group received additional chemotherapy after WBRT (endocrinetreatment unfortunately was not recorded).</p><p>In the contemporary group, 60%of the patients achieved at least a partial remission of their brain metastasesbased on imaging after WBRT (reduction in largest diameter of each lesion by atleast 50% without development of new lesions). At 6 months after WBRT, 59% ofthe patients were progression-free in the central nervous system. These dataare not available for the historical group. Median survival from firstdiagnosis of breast cancer was 102 months in contemporary patients with initialT1/2 N0 disease and 47.5 months in patients with more advanced disease (<italic>P</italic> &#x0003c; .05). These figures are higher than in historical patients (60.9 versus 34.7 months).<xref ref-type="table" rid="tab2"> Table 2</xref> demonstrates that the recent survival improvement from thestart of WBRT is entirely derived from RPA class II patients, while no obvious progresswas achieved in RPA class III. Analysis of class I was not meaningful, as thisgroup included only 2 patients. Only 2 of the contemporary patients in RPAclass III received chemotherapy after WBRT (versus one patient in thehistorical group). Patients without active treatment after WBRT had a mediansurvival of 3.5 versus 3.2 months, that is, no improvement over time. Forpatients with active treatment, median survival also remained stable (9.0 versus7.9 months), while the 1-year survival rate improved from 25 to 43%. The smallgroup (<italic>n</italic> = 6) of patients that received the most aggressive treatment, defined astrastuzumab-containing regimens and/or brain salvage treatment, had a mediansurvival of 15.4 months (4 patients survived &#x0003e;1 year).</p></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>This matched pairs analysiswas performed with two groups of patients, which received identical local treatmentfor their brain metastases and were well balanced for the known prognosticfactors age, KPS, extracranial disease status, graded prognostic assessment(GPA) group, and RPA class. Unlike the newly developed GPA, RPA class has been confirmedas prognostic factor in patients with primary breast cancer in several studies(<xref ref-type="table" rid="tab3">Table 3</xref>). In order to obtain enough historical patients for the matchingprocedure, the treatment period was extended back to the year 1987. Therecently suggested prognostic factor lymphopenia [<xref ref-type="bibr" rid="B4">5</xref>, <xref ref-type="bibr" rid="B5">6</xref>] has not been routinelyassessed in our department and could, therefore, not be included. A furtherpoint that needs to be mentioned is the lack of information on hormone receptorstatus, HER-2 status, and endocrine treatment in the historical patient group,which was treated before 1998. Thus, imbalances regarding these parameters,which might have influenced the survival results to some degree, cannot beruled out. As demonstrated in <xref ref-type="table" rid="tab4">Table 4</xref>, the prognostic impact of hormonereceptor and HER-2 status is difficult to interpret at this time, as thepublished studies reported inconsistent results and are all limited in size. Noneof the patients in the historical group received trastuzumab, taxanes,capecitabine, or new-generation aromatase inhibitors.</p><p>The first interesting findingwas that the interval from initial breast cancer treatment to brain metastaseshas increased by 18 months, that is, 53%. Median interval was longer thanpreviously reported in the literature (<xref ref-type="table" rid="tab3">Table 3</xref>). Accordingly, increased overallsurvival from first diagnosis of breast cancer was evident, in particular inpatients with initial T1/2 N0 disease. Such results might be explained by achange in the biology of the disease. However, the numbers of patients withnode-positive disease, receptor-negative disease, and HER-2 positive diseasebetween 2001 and 2007 argues against this explanation. Especially HER-2overexpression and hormone receptor negativity appear to influence the risk ofbrain metastases development [<xref ref-type="bibr" rid="B16">16</xref>]. In fact, the data favour changes intreatment regimens as a more likely explanation. The use of systemicchemotherapy has increased over time, both before and after the diagnosis ofbrain metastases. However, such treatment was performed nearly exclusively inthose patients with brain metastases that belonged to the prognostically morefavourable groups (better RPA class). Whether changes in systemic treatment arethe only explanation for the marked survival improvement in RPA class II in thepresent study is difficult to assess. Other factors might potentially influencethe results. It is, for example, possible that more patients that previouslywould have been assigned to RPA class I would now be assigned to class II,based on better methods for detection of extracranial metastatic disease. Inaddition, RPA class II is a quite inhomogeneous group of patients with largepotential differences, for example, in extent of CNS involvement and KPS.</p><p>In the present analysis, survivalafter WBRT has remained unchanged in patients without further active treatment. It has improved in prognostically better patients and especially patients thatreceived active treatment, where the 1-year survival rates have almost doubled. As these patient groups were small, confirmation of the results in other seriesshould be attempted. When looking at the literature, the series that is bestcomparable to our own contemporary patients is the one reported by Le Scodan etal. [<xref ref-type="bibr" rid="B5">6</xref>], which provides almost identical survival data (<xref ref-type="table" rid="tab3">Table 3</xref>). The seriesthat included the oldest data (back to 1984) [<xref ref-type="bibr" rid="B7">7</xref>], is very close to our ownhistorical group. Bartsch et al. confirmed that patients without systemictreatment have significantly poorer median survival (5 months versus 10 monthsin patients with systemic treatment) [<xref ref-type="bibr" rid="B8">8</xref>]. These authors also found thatintensified local therapy of brain metastases improved the outcome. Lee et al. confirmed the value of both intensified local and systemic treatment in aseries of 198 patients [<xref ref-type="bibr" rid="B17">17</xref>]. Other nonrandomized series suggest that RS mightlead to better local control and survival than that reported from WBRT series [<xref ref-type="bibr" rid="B18">18</xref>]. The impact of chemotherapy on brain control is less clear [<xref ref-type="bibr" rid="B19">19</xref>], although recentdata suggest that capecitabine might be able to induce remission of centralnervous system metastases from breast cancer [<xref ref-type="bibr" rid="B20">20</xref>]. Taken together, the presentresults and the literature overview are compatible with the hypothesis thatimproved systemic therapy might contribute to longer survival in patients withbrain metastases from breast cancer, which qualify for active systemic therapyin addition to upfront WBRT.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khuntia</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Mehta</surname><given-names>MP</given-names></name></person-group><article-title>Whole-brain radiotherapy in the management of brain metastasis</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2006</year><volume>24</volume><issue>8</issue><fpage>1295</fpage><lpage>1304</lpage><pub-id pub-id-type="pmid">16525185</pub-id></citation></ref><ref id="B6"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sperduto</surname><given-names>PW</given-names></name><name><surname>Berkey</surname><given-names>B</given-names></name><name><surname>Gaspar</surname><given-names>LE</given-names></name><name><surname>Mehta</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>W</given-names></name></person-group><article-title>A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2008</year><volume>70</volume><issue>2</issue><fpage>510</fpage><lpage>514</lpage></citation></ref><ref id="B2"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>L</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Rotman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>1997</year><volume>37</volume><issue>4</issue><fpage>745</fpage><lpage>751</lpage></citation></ref><ref id="B3"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieder</surname><given-names>C</given-names></name><name><surname>Nestle</surname><given-names>U</given-names></name><name><surname>Motaref</surname><given-names>B</given-names></name><name><surname>Walter</surname><given-names>K</given-names></name><name><surname>Niewald</surname><given-names>M</given-names></name><name><surname>Schnabel</surname><given-names>K</given-names></name></person-group><article-title>Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2000</year><volume>46</volume><issue>2</issue><fpage>297</fpage><lpage>302</lpage></citation></ref><ref id="B4"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Claude</surname><given-names>L</given-names></name><name><surname>Perol</surname><given-names>D</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><etal/></person-group><article-title>Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma</article-title><source><italic>Radiotherapy &#x00026; Oncology</italic></source><year>2005</year><volume>76</volume><issue>3</issue><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">16024123</pub-id></citation></ref><ref id="B5"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Scodan</surname><given-names>R</given-names></name><name><surname>Massard</surname><given-names>C</given-names></name><name><surname>Mouret-Fourme</surname><given-names>E</given-names></name><etal/></person-group><article-title>Brain metastases from breast carcinoma: validation of the Radiation Therapy Oncology Group recursive partitioning analysis classification and proposition of a new prognostic score</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2007</year><volume>69</volume><issue>3</issue><fpage>839</fpage><lpage>845</lpage></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud-Ahmed</surname><given-names>AS</given-names></name><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Crownover</surname><given-names>RL</given-names></name><name><surname>Barnett</surname><given-names>GH</given-names></name></person-group><article-title>Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>2002</year><volume>54</volume><issue>3</issue><fpage>810</fpage><lpage>817</lpage></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>R</given-names></name><name><surname>Fromm</surname><given-names>S</given-names></name><name><surname>Rudas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer&#x02014;a retrospective analysis</article-title><source><italic>Radiotherapy &#x00026; Oncology</italic></source><year>2006</year><volume>80</volume><issue>3</issue><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">16959347</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>B-H</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Han</surname><given-names>H-S</given-names></name><etal/></person-group><article-title>Breast cancer subtypes and survival in patients with brain metastases</article-title><source><italic>Breast Cancer Research</italic></source><year>2008</year><volume>10</volume><issue>1, article R20</issue><fpage>1</fpage><lpage>8</lpage></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirsch</surname><given-names>DG</given-names></name><name><surname>Ledezma</surname><given-names>CJ</given-names></name><name><surname>Mathews</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Survival after brain metastases from breast cancer in the trastuzumab era</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2005</year><volume>23</volume><issue>9</issue><fpage>2114</fpage><lpage>2116</lpage><pub-id pub-id-type="pmid">15774813</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eichler</surname><given-names>AF</given-names></name><name><surname>Kuter</surname><given-names>I</given-names></name><name><surname>Ryan</surname><given-names>P</given-names></name><name><surname>Schapira</surname><given-names>L</given-names></name><name><surname>Younger</surname><given-names>J</given-names></name><name><surname>Henson</surname><given-names>JW</given-names></name></person-group><article-title>Survival in patients with brain metastases from breast cancer: the importance of HER-2 status</article-title><source><italic>Cancer</italic></source><year>2008</year><volume>112</volume><issue>11</issue><fpage>2359</fpage><lpage>2367</lpage><pub-id pub-id-type="pmid">18361426</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melisko</surname><given-names>ME</given-names></name><name><surname>Moore</surname><given-names>DH</given-names></name><name><surname>Sneed</surname><given-names>PK</given-names></name><name><surname>De Franco</surname><given-names>J</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name></person-group><article-title>Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2008</year><volume>88</volume><issue>3</issue><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">18398574</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harputluoglu</surname><given-names>H</given-names></name><name><surname>Dizdar</surname><given-names>O</given-names></name><name><surname>Aksoy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characteristics of breast cancer patients with central nervous system metastases: a single-center experience</article-title><source><italic>Journal of the National Medical Association</italic></source><year>2008</year><volume>100</volume><issue>5</issue><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">18507204</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>B-B</given-names></name><name><surname>Uhm</surname><given-names>JE</given-names></name><name><surname>Cho</surname><given-names>EY</given-names></name><etal/></person-group><article-title>Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?</article-title><comment><italic>Cancer Chemotherapy and Pharmacology</italic>. In press</comment></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>DN</given-names></name><name><surname>Modgil</surname><given-names>R</given-names></name><name><surname>Guglani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Extended survival in women with brain metastases from HER2 overexpressing breast cancer</article-title><source><italic>American Journal of Clinical Oncology</italic></source><year>2008</year><volume>31</volume><issue>3</issue><fpage>250</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">18525303</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabos</surname><given-names>Z</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Hanson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2006</year><volume>24</volume><issue>36</issue><fpage>5658</fpage><lpage>5663</lpage><pub-id pub-id-type="pmid">17102066</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Ahn</surname><given-names>J-H</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Brain metastases  in breast cancer: prognostic factors and management</article-title><comment><italic>Breast Cancer Research and Treatment</italic>. In press</comment></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akyurek</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>EL</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer</article-title><source><italic>American Journal of Clinical Oncology</italic></source><year>2007</year><volume>30</volume><issue>3</issue><fpage>310</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">17551311</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieder</surname><given-names>C</given-names></name><name><surname>Grosu</surname><given-names>AL</given-names></name><name><surname>Astner</surname><given-names>S</given-names></name><name><surname>Thamm</surname><given-names>R</given-names></name><name><surname>Molls</surname><given-names>M</given-names></name></person-group><article-title>Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors</article-title><source><italic>Radiation Oncology</italic></source><year>2006</year><volume>1</volume><issue>1, article 19</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16722574</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekenel</surname><given-names>M</given-names></name><name><surname>Hormigo</surname><given-names>AM</given-names></name><name><surname>Peak</surname><given-names>S</given-names></name><name><surname>DeAngelis</surname><given-names>LM</given-names></name><name><surname>Abrey</surname><given-names>LE</given-names></name></person-group><article-title>Capecitabine therapy of central nervous system metastases from breast cancer</article-title><source><italic>Journal of Neuro-Oncology</italic></source><year>2007</year><volume>85</volume><issue>2</issue><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">17611719</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Contemporary group, <italic>n</italic> = 32</th><th align="center" rowspan="1" colspan="1">Historical group, <italic>n</italic> = 32</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median age, range</td><td align="center" rowspan="1" colspan="1">55 yrs., 34&#x02013;81</td><td align="center" rowspan="1" colspan="1">53 yrs., 29&#x02013;72</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Median KPS, range</td><td align="center" rowspan="1" colspan="1">70%, 50&#x02013;90</td><td align="center" rowspan="1" colspan="1">70%, 30&#x02013;90</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Median time interval*</td><td align="center" rowspan="1" colspan="1">52 mo., 3&#x02013;216</td><td align="center" rowspan="1" colspan="1">34 mo., 7&#x02013;118</td><td align="center" rowspan="1" colspan="1">&#x0003c;.05</td></tr><tr><td align="left" rowspan="1" colspan="1">% single brain metastasis</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">&#x0003c;.05</td></tr><tr><td align="left" rowspan="1" colspan="1">% with MRI scan of the brain</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% uncontrolled primary</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% without extracranial metastases</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% RPA class I versus II versus III</td><td align="center" rowspan="1" colspan="1">6 : 59 : 34</td><td align="center" rowspan="1" colspan="1">6 : 56 : 38</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% GPA group I versus II versus III versus IV</td><td align="center" rowspan="1" colspan="1">0 : 0 : 62 : 38</td><td align="center" rowspan="1" colspan="1">0 : 6 : 56 : 38</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Median GPA score</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% chemotherapy before brain metastases diagnosis</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">&#x0003c;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% T1/2 N0 versus T3/4 N0 versus N+</td><td align="center" rowspan="1" colspan="1">25 : 6 : 69</td><td align="center" rowspan="1" colspan="1">19 : 6 : 75</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">% with HR positive tumour</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">not available</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">% with HER-2 positive tumour</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">not available</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>KPS:Karnofsky performance status, * from breast cancer diagnosis to brainmetastases, MRI: magnetic resonance imaging, RPA: recursive partitioninganalysis, GPA: graded prognostic assessment (Sperduto et al. [<xref ref-type="bibr" rid="B6">2</xref>]: 0-1 point(most unfavourable) defined as group IV, 1.5&#x02013;2.5 points defined as group III, 3points defined as group II, 3.5&#x02013;4 points defined as group I), HR: hormonereceptor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Survival results for the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Contemporary group, <italic>n</italic> = 32</th><th align="center" rowspan="1" colspan="1">Historical group, <italic>n</italic> = 32</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value (log-rank test)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median survival</td><td align="center" rowspan="1" colspan="1">5.0 mo.</td><td align="center" rowspan="1" colspan="1">3.6 mo.</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1-year survival</td><td align="center" rowspan="1" colspan="1">31%</td><td align="center" rowspan="1" colspan="1">19%</td><td align="center" rowspan="1" colspan="1">&#x0003c;.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Median survival RPA class II</td><td align="center" rowspan="1" colspan="1">9.0 mo.</td><td align="center" rowspan="1" colspan="1">3.4 mo.</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1-year survival RPA class II</td><td align="center" rowspan="1" colspan="1">42%</td><td align="center" rowspan="1" colspan="1">22%</td><td align="center" rowspan="1" colspan="1">&#x0003c;.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Median survival RPA class III</td><td align="center" rowspan="1" colspan="1">2.4 mo.</td><td align="center" rowspan="1" colspan="1">3.1 mo.</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1-year survival RPA class III</td><td align="center" rowspan="1" colspan="1">18%</td><td align="center" rowspan="1" colspan="1">8%</td><td align="center" rowspan="1" colspan="1">&#x0003e;.1</td></tr></tbody></table></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Comparison with the literature, median WBRT dose 30 Gy in all studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Own contemporary patients</th><th align="center" rowspan="1" colspan="1">Mahmoud-Ahmed et al. [<xref ref-type="bibr" rid="B7">7</xref>]</th><th align="center" rowspan="1" colspan="1">Claude et al. [<xref ref-type="bibr" rid="B4">5</xref>]</th><th align="center" rowspan="1" colspan="1">Bartsch et al. [<xref ref-type="bibr" rid="B8">8</xref>]</th><th align="center" rowspan="1" colspan="1">Le Scodan et al. [<xref ref-type="bibr" rid="B5">6</xref>]</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treated</td><td align="center" rowspan="1" colspan="1">2000&#x02013;2007</td><td align="center" rowspan="1" colspan="1">1984&#x02013;2000</td><td align="center" rowspan="1" colspan="1">1991&#x02013;2001</td><td align="center" rowspan="1" colspan="1">1994&#x02013;2004</td><td align="center" rowspan="1" colspan="1">1998&#x02013;2003</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>n</italic></td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">116</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">174</td><td align="center" rowspan="1" colspan="1">117</td></tr><tr><td align="left" rowspan="1" colspan="1">Upfront surgery/RS</td><td align="center" rowspan="1" colspan="1">no</td><td align="center" rowspan="1" colspan="1">no</td><td align="center" rowspan="1" colspan="1">yes</td><td align="center" rowspan="1" colspan="1">yes</td><td align="center" rowspan="1" colspan="1">no</td></tr><tr><td align="left" rowspan="1" colspan="1">Median age</td><td align="center" rowspan="1" colspan="1">55 y.</td><td align="center" rowspan="1" colspan="1">50 y.</td><td align="center" rowspan="1" colspan="1">54 y.</td><td align="center" rowspan="1" colspan="1">55 y.</td><td align="center" rowspan="1" colspan="1">53 y.</td></tr><tr><td align="left" rowspan="1" colspan="1">Median interval</td><td align="center" rowspan="1" colspan="1">52 m.</td><td align="center" rowspan="1" colspan="1">22.5 m.</td><td align="center" rowspan="1" colspan="1">38 m.</td><td align="center" rowspan="1" colspan="1">35 m.</td><td align="center" rowspan="1" colspan="1">39 m.</td></tr><tr><td align="left" rowspan="1" colspan="1">Extracranial met.</td><td align="center" rowspan="1" colspan="1">91%</td><td align="center" rowspan="1" colspan="1">68%</td><td align="center" rowspan="1" colspan="1">80%</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">94%</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous Ctx</td><td align="center" rowspan="1" colspan="1">81%</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">84%</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">79%</td></tr><tr><td align="left" rowspan="1" colspan="1">HR positive</td><td align="center" rowspan="1" colspan="1">42%</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">66%</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">48%</td></tr><tr><td align="left" rowspan="1" colspan="1">Median survival</td><td align="center" rowspan="1" colspan="1">5.0 m.</td><td align="center" rowspan="1" colspan="1">4.2 m.</td><td align="center" rowspan="1" colspan="1">5.0 m.</td><td align="center" rowspan="1" colspan="1">7.0 m.</td><td align="center" rowspan="1" colspan="1">5.0 m.</td></tr><tr><td align="left" rowspan="1" colspan="1">1-year survival</td><td align="center" rowspan="1" colspan="1">31%</td><td align="center" rowspan="1" colspan="1">17%</td><td align="center" rowspan="1" colspan="1">25%</td><td align="center" rowspan="1" colspan="1">30%</td><td align="center" rowspan="1" colspan="1">28%</td></tr><tr><td align="left" rowspan="1" colspan="1">Median survival class II</td><td align="center" rowspan="1" colspan="1">9.0 m.</td><td align="center" rowspan="1" colspan="1">6.1 m.</td><td align="center" rowspan="1" colspan="1">9.0 m.</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">8.0 m.</td></tr><tr><td align="left" rowspan="1" colspan="1">Median survival class III</td><td align="center" rowspan="1" colspan="1">2.4 m.</td><td align="center" rowspan="1" colspan="1">1.7 m.</td><td align="center" rowspan="1" colspan="1">3.0 m.</td><td align="center" rowspan="1" colspan="1">unknown</td><td align="center" rowspan="1" colspan="1">3.0 m.</td></tr></tbody></table><table-wrap-foot><fn><p>RS: radiosurgery, Ctx: chemotherapy, HR: hormone receptor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Prognostic impact of hormone receptor and HER-2 status.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" rowspan="1" colspan="1">Prognostic impact of hormone receptor status</th><th align="center" rowspan="1" colspan="1">Prognostic impact of HER-2 status</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Claude et al. [<xref ref-type="bibr" rid="B4">5</xref>]</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">none</td><td align="center" rowspan="1" colspan="1">not examined</td></tr><tr><td align="left" rowspan="1" colspan="1">Bartsch et al. [<xref ref-type="bibr" rid="B8">8</xref>]</td><td align="center" rowspan="1" colspan="1">174</td><td align="center" rowspan="1" colspan="1">none</td><td align="center" rowspan="1" colspan="1">none</td></tr><tr><td align="left" rowspan="1" colspan="1">Le Scodan et al. [<xref ref-type="bibr" rid="B5">6</xref>]</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">receptor negative significantly worse</td><td align="center" rowspan="1" colspan="1">none</td></tr><tr><td align="left" rowspan="1" colspan="1">Nam et al. [<xref ref-type="bibr" rid="B9">9</xref>]</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">receptor negative significantly worse</td><td align="center" rowspan="1" colspan="1">HER-2 negative significantly worse</td></tr><tr><td align="left" rowspan="1" colspan="1">Kirsch et al. [<xref ref-type="bibr" rid="B10">10</xref>]</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">not examined</td><td align="center" rowspan="1" colspan="1">HER-2 negative significantly worse*</td></tr><tr><td align="left" rowspan="1" colspan="1">Eichler et al. [<xref ref-type="bibr" rid="B11">11</xref>]</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">none</td><td align="center" rowspan="1" colspan="1">HER-2 negative significantly worse<sup>&#x022c0;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Melisko et al. [<xref ref-type="bibr" rid="B12">12</xref>]</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">receptor negative significantly worse</td><td align="center" rowspan="1" colspan="1">none</td></tr><tr><td align="left" rowspan="1" colspan="1">Harputluoglu et al. [<xref ref-type="bibr" rid="B13">13</xref>]</td><td align="center" rowspan="1" colspan="1">144</td><td align="center" rowspan="1" colspan="1">none</td><td align="center" rowspan="1" colspan="1">none</td></tr><tr><td align="left" rowspan="1" colspan="1">Park et al. [<xref ref-type="bibr" rid="B14">14</xref>]</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">none</td><td align="center" rowspan="1" colspan="1">HER-2 positive significantly worse</td></tr><tr><td align="left" rowspan="1" colspan="1">Church et al. [<xref ref-type="bibr" rid="B15">15</xref>]</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">not examined</td><td align="center" rowspan="1" colspan="1">HER-2 negative significantly worse*</td></tr><tr><td align="left" rowspan="1" colspan="1">Own contemporary group</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">none</td><td align="center" rowspan="1" colspan="1">none</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>&#x022c0;</sup> 80% of HER-2 overexpressing cases received trastuzumab after diagnosis of brain metastases.</p><p>* The difference in survival was limited to patients with HER-2 overexpressing cancer treated with trastuzumab after diagnosis of brain metastases.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>